HKG: 2575

Company Drug

Xuanzhu Biopharma Receives NMPA Approval for Phase III Trial of Anaprazole-Based Quadruple Therapy Against H. pylori

Fineline Cube Apr 15, 2026

Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575) announced it has received regulatory clearance from the National...

Company Drug

Xuanzhu Biopharma Completes Anaprazole Phase III Enrollment – 500‑Subject Reflux Esophagitis Trial Advances Novel PPI

Fineline Cube Mar 23, 2026

Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575) announced completion of full enrollment for its Phase III...

Company Drug

BIREOCCILIB OUTPERFORMS TRADITIONAL CDK4/6 IN BRIGHT‑3: Xuanzhu Biopharma Announces Interim Phase III Results at ESMO 2025

Fineline Cube Oct 22, 2025

Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575) announced that the interim analysis of the Phase III BRIGHT‑3...

Company Deals

Novo Nordisk Partners with OpenAI to Accelerate Drug Discovery and Transform Healthcare Operations

Company Drug

Fosun Pharma Advances Dual-Target CAR-T Therapy FKC289 into Clinical Trials for Rare Kidney and Blood Disorders

Policy / Regulatory

China’s State Council Unveils Comprehensive Drug Pricing Reforms to Strengthen Market-Oriented Mechanisms and Innovation Incentives

Company Drug

Gan & Lee Pharmaceuticals Doses First Patient in Phase III Trial for Novel Long-Acting Insulin GZR33 in Type 2 Diabetes